Phase II trial evaluating continuous infusion of etoposide, cisplatin, and hexamethylmelamine in extensive-disease small cell carcinoma of the lung

S. C. Remick, A. J. Neville, J. K V Willson

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

A total of 27 untreated and 24 previously treated patients with extensive-disease small cell lung cancer (SCLC) were treated with a combination chemotherapeutic regimen of continuous-infusion etoposide for 5 days, cisplatin, and hexamethylmelamine. Of 25 evaluable patients with untreated SCLC, three (12%) achieved a complete response and 16 (64%) achieved a partial response. Among 23 evaluable patients with relapsed SCLC there were no complete responses and nine (39%) achieved a partial response. Median survival times were 252 and 109 days for the above groups, respectively. Myelotoxicity, especially thrombocytopenia, was moderately severe. Other toxic effects, including renal and neurologic, were minimal. These results compare favorably with other regimens including etoposide and cisplatin. Our results further confirm the activity of etoposide and cisplatin as both initial therapy and as a salvage regimen in the management of patients with extensive-stage SCLC.

Original languageEnglish (US)
Pages (from-to)575-580
Number of pages6
JournalCancer Treatment Reports
Volume71
Issue number6
StatePublished - 1987

Fingerprint

Altretamine
Small Cell Lung Carcinoma
Etoposide
Cisplatin
Poisons
Thrombocytopenia
Nervous System
Kidney
Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Phase II trial evaluating continuous infusion of etoposide, cisplatin, and hexamethylmelamine in extensive-disease small cell carcinoma of the lung. / Remick, S. C.; Neville, A. J.; Willson, J. K V.

In: Cancer Treatment Reports, Vol. 71, No. 6, 1987, p. 575-580.

Research output: Contribution to journalArticle

@article{4dbc918a50b34a978d58fd928308875c,
title = "Phase II trial evaluating continuous infusion of etoposide, cisplatin, and hexamethylmelamine in extensive-disease small cell carcinoma of the lung",
abstract = "A total of 27 untreated and 24 previously treated patients with extensive-disease small cell lung cancer (SCLC) were treated with a combination chemotherapeutic regimen of continuous-infusion etoposide for 5 days, cisplatin, and hexamethylmelamine. Of 25 evaluable patients with untreated SCLC, three (12{\%}) achieved a complete response and 16 (64{\%}) achieved a partial response. Among 23 evaluable patients with relapsed SCLC there were no complete responses and nine (39{\%}) achieved a partial response. Median survival times were 252 and 109 days for the above groups, respectively. Myelotoxicity, especially thrombocytopenia, was moderately severe. Other toxic effects, including renal and neurologic, were minimal. These results compare favorably with other regimens including etoposide and cisplatin. Our results further confirm the activity of etoposide and cisplatin as both initial therapy and as a salvage regimen in the management of patients with extensive-stage SCLC.",
author = "Remick, {S. C.} and Neville, {A. J.} and Willson, {J. K V}",
year = "1987",
language = "English (US)",
volume = "71",
pages = "575--580",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "6",

}

TY - JOUR

T1 - Phase II trial evaluating continuous infusion of etoposide, cisplatin, and hexamethylmelamine in extensive-disease small cell carcinoma of the lung

AU - Remick, S. C.

AU - Neville, A. J.

AU - Willson, J. K V

PY - 1987

Y1 - 1987

N2 - A total of 27 untreated and 24 previously treated patients with extensive-disease small cell lung cancer (SCLC) were treated with a combination chemotherapeutic regimen of continuous-infusion etoposide for 5 days, cisplatin, and hexamethylmelamine. Of 25 evaluable patients with untreated SCLC, three (12%) achieved a complete response and 16 (64%) achieved a partial response. Among 23 evaluable patients with relapsed SCLC there were no complete responses and nine (39%) achieved a partial response. Median survival times were 252 and 109 days for the above groups, respectively. Myelotoxicity, especially thrombocytopenia, was moderately severe. Other toxic effects, including renal and neurologic, were minimal. These results compare favorably with other regimens including etoposide and cisplatin. Our results further confirm the activity of etoposide and cisplatin as both initial therapy and as a salvage regimen in the management of patients with extensive-stage SCLC.

AB - A total of 27 untreated and 24 previously treated patients with extensive-disease small cell lung cancer (SCLC) were treated with a combination chemotherapeutic regimen of continuous-infusion etoposide for 5 days, cisplatin, and hexamethylmelamine. Of 25 evaluable patients with untreated SCLC, three (12%) achieved a complete response and 16 (64%) achieved a partial response. Among 23 evaluable patients with relapsed SCLC there were no complete responses and nine (39%) achieved a partial response. Median survival times were 252 and 109 days for the above groups, respectively. Myelotoxicity, especially thrombocytopenia, was moderately severe. Other toxic effects, including renal and neurologic, were minimal. These results compare favorably with other regimens including etoposide and cisplatin. Our results further confirm the activity of etoposide and cisplatin as both initial therapy and as a salvage regimen in the management of patients with extensive-stage SCLC.

UR - http://www.scopus.com/inward/record.url?scp=0023275697&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023275697&partnerID=8YFLogxK

M3 - Article

C2 - 3034422

AN - SCOPUS:0023275697

VL - 71

SP - 575

EP - 580

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 6

ER -